SciELO - Scientific Electronic Library Online

 
vol.59 número10Metodología diagnóstica ante la recidiva bioquímica después de braquiterapiaEl tiempo de doblaje de PSA como nuevo método diagnóstico y pronóstico del cáncer de próstata índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Em processo de indexaçãoCitado por Google
  • Não possue artigos similaresSimilares em SciELO
  • Em processo de indexaçãoSimilares em Google

Compartilhar


Archivos Españoles de Urología (Ed. impresa)

versão impressa ISSN 0004-0614

Resumo

GOMEZ VEIGA, F. et al. Current role of PSA and other markers in the diagnosis of prostate cancer. Arch. Esp. Urol. [online]. 2006, vol.59, n.10, pp.1069-1082. ISSN 0004-0614.

Objectives: To evaluate the current role of PSA as a diagnostic method for prostate cancer, as well as to analyze possible new markers. Methods: We perform a bibliographic review for PSA, and its molecular forms, as a marker to define the presence of prostate cancer. We review the factors related to PSA modifications, predictive models, or the current controversies about the usefulness of its cutpoint to define the risk of prostate cancer or the marker itself. We analyze possible new markers and the most interesting work lines in the development of new markers. We used MEDLINE for the bibliographic search. Results: Available data confirm that PSA has a high sensitivity; although specificity is low, mainly in the ≤ 10ng/ml range, it may be increased with the use of various molecular isoforms, ratios or predictive models. Nevertheless, it is true that despite such studies it is difficult to increase specificity, so biopsies are reduced. Currently we have new markers, some of them already marketed, others in development, which seem to improve the specificity of PSA (isoforms, use of molecular biology). Conclusions: PSA is still the standard marker for the diagnosis of prostate cancer. It is important to improve the specificity; therefore we need new predictive models or new isoforms that help us to do a better selection of candidates for biopsy. There are various promising research lines with new markers, but there is not ideal substitute for PSA yet.

Palavras-chave : PSA; Prostatic cancer.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )

 

Creative Commons License Todo o conteúdo deste periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons